Johnston, Stephen

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: A Randomized Clinical Trial

Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2020) · JAMA Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 991

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer

Fribbens, C., O’Leary, B., Kilburn, L., Hrebien, S., Garcia-Murillas, I., Beaney, M., Cristofanilli, M., Andre, F., Loi, S., Loibl, S., et al. (2016) · Journal of Clinical Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 722

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

Johnston, S., Martin, M., Di Leo, A., Im, S.-A., Awada, A., Forrester, T., Frenzel, M., Hardebeck, M. C., Cox, J., Barriga, S., et al. (2019) · npj Breast Cancer

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 685

Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant

Spoerke, J. M., Gendreau, S., Walter, K., Qiu, J., Wilson, T. R., Savage, H., Aimi, J., Derynck, M. K., Chen, M., Chan, I. T., et al. (2016) · Nature Communications

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 309

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial

Johnston, S. R., Kilburn, L. S., Ellis, P., Dodwell, D., Cameron, D., Hayward, L., Im, Y.-H., Braybrooke, J. P., Brunt, A. M., Cheung, K.-L., et al. (2013) · The Lancet Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 274

Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3.

Goetz, M. P., Toi, M., Huober, J., Sohn, J., Trédan, O., Park, I. H., Campone, M., Chen, S.-C., Manso, L. M., Paluch-Shimon, S., et al. (2024) · Annals of Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 238

LBA15 MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC)

Goetz, M. P., Toi, M., Huober, J., Sohn, J., Tredan, O., Park, I. H., Campone, M., Chen, S. C., Sanchez, L. M. M., Paluch-Shimon, S., et al. (2022) · Annals of Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 96

Enhancing Endocrine Therapy for Hormone Receptor–Positive Advanced Breast Cancer: Cotargeting Signaling Pathways

Johnston, S. R. D. (2015) · Journal of the National Cancer Institute

Advanced Breast Cancer TherapiesEstrogen and related hormone effects

Cited by 92

Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy

Di Leo, A., O’Shaughnessy, J., Sledge, G. W., Martin, M., Lin, Y., Frenzel, M., Hardebeck, M. C., Smith, I. C., Llombart-Cussac, A., Goetz, M. P., et al. (2018) · npj Breast Cancer

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 66